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Abstract We used the PCR (polymerase chain reaction) to amplify fragments of glucagon receptor DNA from genomic DNA. Sequencing of the 
subcloned fragments demonstrated that genomic DNA encoding the glucagon receptor spans over 12 exons interrupted by 11introns. The introns 
were located mainly at the 5' end and in the core domain of the glucagon receptor CDS totalling 23 kb. Intron positions were similar to the positions 
of introns in growth hormone-releasing hormone receptor and parathyroid hormone receptor, two receptors belonging to the same receptor family 
as the glucagon receptor. This high number of introns might be the cause of the mRNA polymorphism observed at the 5' end: when PCR was 
performed on cDNA using primers amplifying the central or 3' end cDNA fragments, a single band corresponding to the cloned cDNA was observed. 
In contrast, if primers amplifying cDNA fragments corresponding tonucleotides -8 to 680 of CDS were used, cDNA fragments of approximately 
500 bp, 600 bp, 700 bp, 800 bp and 900 bp were specifically and reproducibly amplified. Sequencing of these fragments showed either incomplete 
intron removal or splicing at alternative positions. Two of these sequenced variants were translatable in putative glucagon receptor variants: 
(1) unsplicing of intron III (81 bp) gave an additional 27 amino acid sequence after Lys 9~ in the N-terminal domain of the receptor. In the liver, where 
the normal CDS represented about one third of the mRNA molecules, this mRNA variant represented 18% of total mRNA forms; (2) a 21 bp deletion 
in exon V giving rise to a putative deletion of 7 amino acids in glucagon receptor (A64-84 CDS) was also relatively abundant in the liver (10%). The 
observed polymorphism of the glucagon receptor mRNA may contribute to the regulation of glucagon receptor expression and perhaps to the 
heterogeneity of these receptors. 
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1. Introduction 
The primary physiological role of glucagon, together with 
insulin, is the maintenance of the normal glycemia [1]. We 
reported [2,3] simultaneously with Jelinek et al. [4] the cloning 
and the expression of the hepatic glucagon receptor. At vari- 
ance with Jelinek et al. [4] which used expression cloning, our 
DNA directed approach allowed the detection of introns in the 
glucagon receptor gene [2], revealing the possibility of alterna- 
tive splicing and thus of receptor heterogeneity. The sequence 
of the human glucagon receptor, with 82% identity with the rat 
receptor amino acids sequence was recently reported [5]. 
Most of glucagon effects are mediated by the cyclic AMP 
increase due to the activation of adenylate cyclase resulting 
from interaction of glucagon with specific receptors of the liver 
plasma membrane. However glucagon receptor may also be 
coupled to the phospholipase C activation cascade [4]. Glu- 
cagon receptors are primarily found in liver, but were also 
identified in heart [6-8] and other tissues (see refs. in [5]). 
Glucagon receptors belong to a distinct family of seven trans- 
membrane helices receptors which includes receptors for pep- 
tides structurally related to glucagon such as the receptors for 
GLP-I  [9], secretin [10], VIP [11,12], growth hormone-releasing 
hormone (GH-RH receptor) [13] and PACAP [14-16] as well 
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as receptors for peptides apparently unrelated o glucagon such 
as calcitonin receptors [17] and parathyroid hormone receptor 
[18]. 
In this paper we used the PCR approach to clone and se- 
quence eleven introns in the rat genomic DNA encoding the 
glucagon receptor and we describe how these intronic se- 
quences may generate multiple alternative splicing of the rat 
glucagon receptor mRNA.  
2. Materials and methods 
2.1. Sequencing of glucagon receptor gene 
Genomic DNA was purified from rat liver using the ASAP kit 
(Boehringer). PCR amplification of 0.5/lg of genomic DNA was per- 
formed using 0.25 /tM of the forward and reverse oligonucleotides 
primers indicated as feature in Genbank accession o. L31574. Ampli- 
fication began by 'hot start', i.e. 1/.tl of diluted Taq polymerase was 
added after 3 min preincubation of the samples at 95°C. The cycling 
conditions were: 1 min 94°C, 1 min 60°C and 3 min 72°C; 30 cycles 
in PHC-2 apparatus (Techne). 
Amplified DNA (fragments I (nt -19 to 703 CDS) and III (nt 963 
to 1498 CDS)) were blunt-ended by a T4 DNA polymerase and the 5' 
ends were phosphorylated using T4 polynucleotide kinase as described 
in [19]. The kinase treated DNA was ligated with a phosphatase treated 
pUCI8 using the 'Prime efficiency blunt-end ligation kit' (Clontech) 
and 1/.tl aliquots were used to transform 20/11 of competent XL-I blue 
cells using a standard protocol [19]. The amplified DNA fragment II
(nt 587 to 1451 CDS) was subcloned in pCR II plasmid using a TA- 
cloning kit (Invitrogen). The recombinant plasmid of the selected clones 
was purified using the Quiagen midi kit. 
The DNA was denatured by NaOH and sequenced in both strands 
using Sequanase version 2.0 kit (U.S.B. Cleveland). 
2.2. Sequencing of multiple cDNA fragments produced by RT-PCR of 
glucagon receptor 
Total RNA was isolated from guanidine isothiocyanate solubilized 
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liver and heart by centrifugation  cesium chloride gradients as de-
scribed in Sambrook et al.[19]. 
Single stranded cDNA was obtained from 1 #gof total RNA by 
reverse transcription in 20#1 reaction mix using the Superscript II kit 
(BRL). After 40 min incubation at 37°C and 20 min at 42°C, the 
medium was overlayed with mineral oil, diluted with 30 #1 of 10 mM 
EDTA and incubated for 5 min at 100 °C. 
One/.tl of single strand DNA solution was amplified in 20 #1 PCR 
medium (Cetus) using 0.25 ,uM of the forward and reverse primers 
described in the legends, as described above. 
The amplified cDNA fragments were subcloned in pCR II using the 
TA-cloning kit (Invitrogen). I  the heart, the selection of the recombi- 
nant plasmids was based on the estimation of the insert size after EcoRI 
digestion of mini-preps of randomly selected bacterial colonies. In th  
liver, ddA track sequencing was performed using a Taq sequencing kit 
of USB on mini-preps of 40 randomly selected bacterial colonies. The 
number of identical ddA tracks gave a rough estimate of the proportion 
of this sequence in the reactional mixture. The recombinant plasmid of 
the selected clones were purified with the Quiagen kit and sequenced 
as described above. 
3. Results 
We compared the size of the DNA fragments obtained after 
PCR amplification of rat genomic DNA and of the cloned 
glucagon receptor cDNA. The amplified fragments covered the 
whole coding sequence of the glucagon receptor. The difference 
in the size of the compared fragments indicated the presence of 
additional intronic sequences totalling 2.3 kb. The fragments 
amplified between the three pairs of primers were subcloned 
and sequenced (Genbank accession o. L31574). Fig. 1 shows 
the intron/exon rganisation of the glucagon receptor gene: the 
glucagon receptor coding domain (CDS) was interrupted by 
eleven introns: the larger (intron II) was 896 bp long but the 
majority of the introns were small, only 74 to 114 bp. Intron 
XI was the only intron present in the domain coding for the 
putative intracellular C-terminal tail of this receptor. The other 
introns were uniformly distributed throughout the rest of the 
molecule. 
In frame translation of intron III (81 bp) would give an 
additional sequence of 27 amino acids. The other ten introns 
gave stop codons hortly after the beginning of the translation. 
However. intron XI might also theoretically yield a variant 
receptor: in-frame translation of this intron, which is located 
after seventh putative transmembrane domain, would give a 
sequence of 23 amino acids before the stop codon. 
We have no experimental evidence for the real existence of 
an intron XI receptor variant: using a pair of primers flanking 
this intron, a single DNA fragment was amplified by RT-PCR 
in both liver and heart in two rat strains (Fig. 2B). In contrast, 
Fig. 2A and 2B shows that two different pairs of primers ampli- 
fying by RT-PCR the 5' moiety of the glucagon receptor 
mRNA gave several DNA fragments of either higher or lower 
size that the cloned glucagon receptor cDNA. 
The pattern was different in the liver and in the heart. As 
shown in Fig. 2A, two major bands of 700 bp and 800 bp were 
prominent in the liver. The 700 bp corresponded to the size of 
678 bp of the cloned cDNA (nt: -8 to 670). In addition, two 
minor bands of 600 bp and 900 bp were systematically detected. 
In the heart, the same four bands were amplified with similar 
intensities. In addition, minor smaller bands were reproducibly 
amplified. 
The observed polymorphism could reflect a real glucagon 
receptor mRNA polymorphism, or might originate from errors 
in cDNA synthesis or PCR amplification. The following obser- 
vations uggest hat the observed polymorphism was not ar- 
tefactual: (1) the same pattern was obtained from one batch of 
liver RNA using either the Superscript II kit (an RNase H- 
derivative of Maloney Murine Leukemia virus (M-MLV)) and 
reverse transcriptase (BRL) or the RT-PCR kit (Cetus), with 
either oligo(dT) or random oligonucleotide h xamer primers, 
and incubating either at 37°C or at 42°C; (2) the same pattern 
was observed using two different pairs of primers amplifying 
the same 5' end domain but not with primers amplifying the 3' 
end domains. On the other hand amplification of genomic 
DNA gave only one band with all the primers (data not shown). 
Sequencing of alternatively spliced DNA fragments from 
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Fig. 2. Detection by RT-PCR of the 3' and 5' end of the glucagon 
receptor mRNA. Comparison of the liver and the heart. (Panel A) 
RT-PCR of the glucagon receptor mRNA using primers amplifying the 
cDNA fragment nt: -8 to 680 (5' end of CDS) of the heart (H) and liver 
(L) mRNA (C is negative control). (Panel B) RT-PCR of the glucagon 
receptor mRNA using primers amplifying the cDNA fragments nt: 
963-1472 (3' end of CDS) (lanes 14) or nt -41 to 586 (5' end of CDS) 
(lanes 5-8), using the heart (H) and liver (L) mRNA from Wistar-Kyoto 
(WkY) and lean Ziicker (LZk) rats. 
liver and heart was performed after subcloning in pCRII vec- 
tor. The 5' end polymorphism arose from three kinds of alter- 
native splicing: (1) unsplicing of intron(s) (incomplete matura- 
tion); (2) splicing of two or more introns together with central 
exon(s); (3) splicing at a wrong place. Fig. 3 summarizes the 
major alternative splicing observed in the glucagon receptor 
mRNA. 
In the liver 13 of 40 randomly selected clones corresponded 
to the mature CDS and 7 included the unspliced intron III (+81 
bp). Unsplicing of intron III gave a translatable mRNA: such 
putative variants of the glucagon receptor will have 27 addi- 
tional amino acids (GNGVVSAWEAEGAKSGSGLTRAY- 
THVP) inserted after lysine 91 in the N-terminal domain of the 
glucagon receptor. This intron III+ variant represented the 
second most important form in the liver and was the major 
constituent of the 800 bp band of Fig. 2A (where CDS band 
had 700 bp). Smaller amounts of cDNA molecules with un- 
spliced intron IV (+95 bp) and intron V (+85 bp) were also 
detected in the 800 bp band of both tissues tested. Unsplicing 
of these two introns in the same mRNA molecule contributed 
to the 900 band in Fig. 2A. 
The bands with a molecular weight lower than the CDS also 
corresponded to a mixture of cDNA fragments of very similar 
size: the band of 600 bp in Fig. 2A is a mixture of the in block 
splicing [intron I + exon II + intron II] (-103 bp) and [intron 
IV + exon V + intron V] ( -  107 bp). The mRNA molecule which 
had both 'in block' splicing contributed to the band of 500 bp. 
Smaller bands observed in the heart were due mainly to the in 
block splicing at wrong"places, having often similar sequence 
(for instance, splicing 1203 to 1807 of the sequence L31574 gave 
A 187-526 CDS; -389 bp). All of these splicing gave rise to 
cDNA fragments with stop codons before the transmembrane 
domains. 
Another potentially interesting variant of the glucagon re- 
ceptor mRNA was present in the 700 bp ('normal CDS') band 
of Fig. 2A: of 40 randomly selected clones, wefound 4 clones 
with a deletion of the first 21 nt of exon 2 (giving after transla- 
tion a glucagon receptor variant with a 7 amino acids deletion 
(no. 22-28, PKAPSAQ) in the N-terminal domain of the glu- 
cagon receptor) as compared to 13 clones corresponding to the 
normal CDS 
4. Discussion 
The serpentine receptors were initially believed to be essen- 
tially intronless [20]. However, in the last few years, many 
intron-containing receptors were described and a potential role 
for alternative splicing generated receptor heterogeneity was 
suggested in several cases. Three groups of alternatively spliced 
variants can be distinguished: 
1. Alternative splicing concerning the intron located after 
the domain encoding the transmembrane r gions and con- 
sequently producing receptors variants with an alternative 
C-terminal tail (somatostatin receptor [21], prostaglandin EP 3 
receptor [22,23]). 
2. Alternative splicing may generate variants with additional 
exon sequences in the putative third intracellular loop of the 
receptor (for example, in the glucagon receptor family: the 
PACAP receptors [15,16]). 
3. Alternative splicing may also introduce stop codons be- 
fore the end' of the transmembrane domains, so that only trun- 
cated receptor variants can be translated (glycoprotein 
hormone receptors [24-26]). 
The coding domain of the rat glucagon receptor gene spans 
12 exons and 11 introns. This intron number is very high and 
compared with the number of introns in the glycoprotein recep- 
tors such as TSH receptors. However in the case of the 
glycoprotein hormone receptors, all introns were located in the 
domain encoding the N-terminal extracellular domain and the 
rest of the genes were intronless (see Takeshita et al. [24]). The 
eleven introns of the glucagon receptor gene totalized 2350 bp. 
This is relatively short so that the coding domain of the glu- 
cagon receptor gene had 4 kb, as compared to 50 kb for the 
TSH receptor [24] and substance P receptor [27]. 
The glucagon receptor belongs to the minor class II of recep- 
tors of the 'secretin-receptor ype' [2-4] which includes the 
receptors for secretin [10]. GLP-1 [9], VIP~ [11], VIP2 [12], 
PACAP [14-16], GH-RH [13], PTH [18] and calcitonin [17]. 
We had already described four introns (IV, V, VI and XI) 
in immature mRNA during the cloning of the cDNA of this 
receptor [2]. The presence of at least one intron was described 
in the GH-RH receptor [13] and PACAP receptor [15,16] and 
its alternative splicing leads to the receptor variants with longer 
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MAJOR ALTERNATIVE  SPL1CINGS RESPONSIBLE  FOR 
THE POLYMORPH/SM OF THE GLUCAGON RECEPTOR mRNA 
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Fig. 3. Alternative splicing of some glucagon receptor mRNA variants. Major alternative splicing causing the polymorphism of glucagon receptor 
mRNA. The first column summarizes the type of splicing described in the second column. The third column indicates the modification of the mRNA 
size (as compared to normal CDS). The last column indicates the effect oft is spli ing on translation i to a putative receptor variant. 
third intracellular loops (case 2, described above). Two recently 
described variants of the human VIP receptor [28] may also be 
due to the unsplicing of some introns at the 5' end of this 
receptor. 
Lin et al. reported in 1993 [29] the position of 12 introns in 
the mouse growth hormone-releasing factor receptor (GH-RH 
receptor). With the exception of the 1 lth intron which is not 
found in the glucagon receptor gene, the position of the gene 
introns is imilar to the position of the glucagon receptor in- 
trons. The sequence and the size of this GH-RH receptor gene 
introns was not reported. Recently, the entire sequence of 
mouse PTH receptor gene was reported [30]. The coding se- 
quence spans 35 kb and is interrupted by 12 introns, at posi- 
tions similar to the GRF and glucagon receptor gene introns, 
suggesting that these genes diverged from a common ancestor 
[30] .  
The polymorphism of the rat glucagon receptor mRNA in 
the liver originates mainly from unsplicing of intron III, giving 
a potentially translatable s quence. The forms of lower molec- 
ular weight arise from in block splicing of exon II (-103 bp), 
exon V (-107 bp) or both (-210 bp). 
In addition we observed splicing in other places than the 
canonic exon-intron junctions. This generally generated 
mRNAs with a stop codon before the transmembrane domains. 
The only potentially interesting variant in this category corre- 
sponded to the deletion of the first 21 bp in exon II, translatable 
into a putative receptor with a seven amino acid deletion in the 
N-terminal domain. If the two translatable mRNA variants are 
really translated in active proteins, these variant receptors 
might have other pharmacological properties, or perhaps bind 
active glucagon fragments [8]. Transfection studies are required 
to study the activity of these variants. 
The mRNA polymorphism pattern was different in the liver 
and heart (Figs. 1 and 2) as well as in kidney, adipose tissue or 
adrenal gland (Maget, Tastenoy and Svoboda, submitted) and 
for each tissue, the pattern was reproducible. This suggested 
that a specific maturation machinery is found in each tissue, a 
process which may contribute to the regulation of the glucagon 
receptor expression (as observed for tissue-specific expression 
of endothelin-2 [31]. 
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